Arndt Vogel: LIFT-HCC-1 Study Examines Immunotherapy Before Liver Transplantation in HCC
Arndt Vogel/aasld.org

Arndt Vogel: LIFT-HCC-1 Study Examines Immunotherapy Before Liver Transplantation in HCC

Arndt Vogel, Professor at the University of Toronto and Longo Family Chair in Liver Cancer Research at University Health Network, shared on X:

“Off the press!Pre-Liver Transplant Immunotherapy and Post-Transplant Outcomes in HCC: Global LIFT-HCC-1 Study

  • 408 patients.
  • Tumor burden and AFP at liver transplantation associated with HCC recurrence.
  • Rejection associated with non-HBV etiology, immune-related adverse events (irAEs), age and shorter ICI washout.

Pre-transplant immune checkpoint inhibitor therapy appears feasible, but its clinical utility still needs to be established.

Read the full article.”

Arndt Vogel: LIFT-HCC-1 Study Examines Immunotherapy Before Liver Transplantation in HCC

Other articles about Liver Cancer on OncoDaily.

You can also read: Hans Christian Andersen’s Cause of Death: His Final Journey With Liver Cancer

Arndt Vogel: LIFT-HCC-1 Study Examines Immunotherapy Before Liver Transplantation in HCC